NatureWise Biotech & Medicals Corp

NatureWise Biotech & Medicals Corp maintains a strong liquidity position with a current ratio of 15.28, indicating a significant buffer of current assets over current liabilities. The company holds TWD 319.95 million in cash and equivalents, which is 37.9% of total assets, and has no long-term debt, resulting in a debt-to-equity ratio of 0.0. This liquidity profile supports operational flexibility and resilience against short-term financial shocks. Profitability metrics reveal a mixed picture. The company reported a net income of TWD 897,000 on revenue of TWD 224.32 million, translating to a net margin of 0.4%. Return on equity (ROE) and return on assets (ROA) are 0.12% and 0.11%, respectively, both below the industry median for Pharmaceuticals, which typically exceeds 5% ROE and 3% ROA. These figures suggest underperformance in capital efficiency and asset utilization relative to peers. Revenue is concentrated in disclosed segments, though the company does not provide a detailed breakdown of segment performance. The primary focus on medicines and healthcare products implies exposure to domestic and international healthcare demand, with potential geographic concentration in the domestic market. No specific revenue concentration by geography is disclosed, but the company's distribution strategy emphasizes domestic and overseas markets. Growth trajectory is constrained by recent financial performance. Revenue in the latest period is TWD 224.32 million, with no prior-year data provided for comparison. However, the operating loss of TWD 12.02 million and negative operating cash flow of TWD 2.8 million suggest operational challenges. The outlook for the current and next fiscal years is not explicitly provided, but the absence of positive momentum in revenue or profitability raises concerns about near-term growth. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure is free of long-term debt and has no dilution pressure from shares outstanding, with basic and diluted shares equal at 48.19 million. However, the operating loss and negative operating cash flow signal potential liquidity risk if cash burn persists. No dilution sources are identified in filings or transcripts. Recent events include the 2024 annual report filing, which disclosed the financial snapshot and valuation metrics. No material events such as acquisitions, regulatory actions, or major product launches were reported in the latest filings. The company's focus remains on its core product lines, with no indication of strategic shifts or new market entries.